Clinicopathological review of 46 primary retroperitoneal tumors

被引:26
作者
Tambo, Mitsuhiro [1 ]
Fujimoto, Kiyohide [1 ]
Miyake, Makito [1 ]
Hoshiyama, Fumiaki [1 ]
Matsushita, Chie [1 ]
Hirao, Yoshihiko [1 ]
机构
[1] Nara Med Univ, Dept Urol, Kashihara, Nara 6348522, Japan
关键词
clinicopathological parameter; imaging diagnosis; primary retroperitoneal tumor;
D O I
10.1111/j.1442-2042.2007.01839.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To clarify the clinical factors including diagnostic imaging findings that may correlate with the histopathological malignancy in primary retroperitoneal tumors. Methods: The clinical backgrounds and imaging findings of 22 benign and 24 malignant primary retroperitoneal tumors were retrospectively investigated, and the prognosis of patients with malignant retroperitoneal tumors was assessed. Results: There were significant correlations between the presence of symptoms and malignancy (P < 0.01), as well as between the irregularity of tumor margins and malignancy (P < 0.01). On dynamic magnetic resonance imaging (MRI), 90% of malignant tumors showed early enhancement either with quick or slow washout, while 75% of benign tumors showed delayed and no enhancement (P < 0.002). All malignant and benign paraganglioma showed the same early enhancement with quick washout. Malignant lymphoma showed various enhancement patterns. The 2-year and 5-year cause-specific survival rates of the patients with malignant retroperitoneal tumors were 68.0% and 43.2%, respectively. All malignant lymphoma patients were mainly treated with chemotherapy after being diagnosed histologically. Malignant paraganglioma patients who could not meet complete resection needed chemotherapy for promising survival. Conclusion: The symptoms, the irregularity of the margins, and the specific enhancement pattern on the dynamic MRI may be important predictive factors of the primary malignant retroperitoneal tumors. Histological diagnosis was needed for malignant definition of paraganglioma because both benign and malignant paraganglioma showed similar clinical and imaging findings. Preoperative biopsy should be considered for selection of the appropriate treatment particularly in patients that are likely to have malignant lymphoma that could not be diagnosed definitively by the clinical and imaging findings.
引用
收藏
页码:785 / 788
页数:4
相关论文
共 12 条
[1]   MALIGNANT PHEOCHROMOCYTOMA - EFFECTIVE TREATMENT WITH A COMBINATION OF CYCLOPHOSPHAMIDE, VINCRISTINE, AND DACARBAZINE [J].
AVERBUCH, SD ;
STEAKLEY, CS ;
YOUNG, RC ;
GELMANN, EP ;
GOLDSTEIN, DS ;
STULL, R ;
KEISER, HR .
ANNALS OF INTERNAL MEDICINE, 1988, 109 (04) :267-273
[2]   The management of benign and malignant pheochromocytoma and abdominal paraganglioma [J].
Elder, EE ;
Skog, ALH ;
Höög, A ;
Hamberger, B .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2003, 29 (03) :278-283
[3]   COMPARISON OF A STANDARD REGIMEN (CHOP) WITH 3 INTENSIVE CHEMOTHERAPY REGIMENS FOR ADVANCED NON-HODGKINS-LYMPHOMA [J].
FISHER, RI ;
GAYNOR, ER ;
DAHLBERG, S ;
OKEN, MM ;
GROGAN, TM ;
MIZE, EM ;
GLICK, JH ;
COLTMAN, CA ;
MILLER, TP .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (14) :1002-1006
[4]   Prognostic factors associated with long-term survival for retroperitoneal sarcoma: Implications for management [J].
Heslin, MJ ;
Lewis, JJ ;
Nadler, E ;
Newman, E ;
Woodruff, JM ;
Casper, ES ;
Leung, D ;
Brennan, MF .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (08) :2832-2839
[5]   Primary retroperitoneal soft tissue sarcomas: Results of aggressive surgical treatment [J].
Malerba, M ;
Doglietto, GB ;
Pacelli, F ;
Carriero, C ;
Caprino, P ;
Piccioni, E ;
Crucitti, P ;
Crucitti, F .
WORLD JOURNAL OF SURGERY, 1999, 23 (07) :670-675
[6]  
Marcove RC, 1987, SURGICAL MANAGEMENT, P203
[7]  
Nakashima J, 1997, Int J Urol, V4, P441, DOI 10.1111/j.1442-2042.1997.tb00282.x
[8]   MR imaging of soft-tissue masses of the extraperitoneal spaces [J].
Nishimura, H ;
Zhang, Y ;
Ohkuma, K ;
Uchida, M ;
Hayabuchi, N ;
Sun, SL .
RADIOGRAPHICS, 2001, 21 (05) :1141-1154
[9]  
Ohno Hitoshi, 2002, Rinsho Ketsueki, V43, P170
[10]   Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy [J].
Sisson, JC ;
Shapiro, B ;
Shulkin, BL ;
Urba, S ;
Zempel, S ;
Spaulding, S .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (04) :364-370